Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDH17 biparatopic antibody
- Development stage
- Preclinical
- Lead developer
- NovaRock Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Intratumoral, Oral, Inhalation
01
Overview
CDH17 biparatopic antibody is a preclinical-stage therapeutic candidate being developed by NovaRock Biotherapeutics for the treatment of gastrointestinal malignancies, including colon, gastric, and pancreatic cancers. The antibody is designed with a biparatopic architecture, meaning it simultaneously targets two non-overlapping epitopes on Cadherin-17 (CDH17), a cell adhesion protein that is highly and specifically expressed in the gastrointestinal tract and overexpressed in various GI tumors. This biparatopic binding strategy is intended to enhance tumor-specific binding and promote rapid internalization of the antibody-receptor complex. NovaRock is specifically developing this molecule as a platform for an antibody-drug conjugate (ADC), aiming to deliver potent cytotoxic payloads directly into CDH17-positive cancer cells while minimizing off-target toxicity.
- Other names
- CDH17 Biparatopic antibody for ADCCDH-17 Biparatopic antibody for ADCCDH 17 Biparatopic antibody for ADCCDH17 biparatopicCDH-17 biparatopicCDH 17 biparatopic
02
Targets
CDH17 (Cadherin-17)
Beyond the preview
Go deeper on CDH17 biparatopic antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDH17 biparatopic antibody.